Point72 Asia Singapore Pte. Ltd. Takes $26,000 Position in Eyenovia, Inc. (NASDAQ:EYEN)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eyenovia, Inc. (NASDAQ:EYEN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 43,784 shares of the company’s stock, valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.08% of Eyenovia at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EYEN. Armistice Capital LLC increased its holdings in shares of Eyenovia by 41.8% during the fourth quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock worth $9,106,000 after buying an additional 1,290,979 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Eyenovia by 25.2% during the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after purchasing an additional 360,924 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after purchasing an additional 205,390 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its stake in shares of Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares during the period. Finally, Ground Swell Capital LLC bought a new position in Eyenovia in the 2nd quarter valued at approximately $27,000. Institutional investors own 25.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on EYEN shares. William Blair upgraded shares of Eyenovia to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Eyenovia in a research report on Tuesday, August 13th.

Insider Activity

In other Eyenovia news, CEO Michael M. Rowe bought 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the purchase, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.10% of the stock is owned by company insiders.

Eyenovia Stock Down 2.3 %

Eyenovia stock opened at $0.50 on Wednesday. The firm has a market cap of $27.19 million, a price-to-earnings ratio of -0.67 and a beta of 1.74. Eyenovia, Inc. has a 52-week low of $0.37 and a 52-week high of $2.57. The company has a debt-to-equity ratio of 3.72, a quick ratio of 0.27 and a current ratio of 0.46. The firm has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $0.79.

Eyenovia (NASDAQ:EYEN) last announced its earnings results on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.38 million. Equities analysts predict that Eyenovia, Inc. will post -0.57 EPS for the current year.

Eyenovia Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.